Santen Publishes its Annual Integrated Report “Santen Report 2023”

September 13, 2023, Osaka, Japan – Santen Pharmaceutical Co., Ltd. (hereinafter Santen) today announced the release of the “Santen Report 2023” (Integrated Report for the fiscal year ended March 31, 2023). Available in both English and Japanese, the report is a comprehensive source of financial and non-financial information. The report can be accessed on Santen’s investor relations (IR) website (

Since its establishment in Japan in 1890, and guided by its CORE PRINCIPLE, “Tenki ni sanyo suru,” Santen has been committed to helping people maintain and improve their eye health for more than 130 years. As a specialty company focusing on eye health that is committed to demonstrating the value of “People Centricity” in every aspect of the company’s activities, Santen aspires to realize “Happiness with Vision” by providing valuable products and services to consumers, patients, and medical professionals around the world.

This edition of the report includes Santen’s medium-term strategies for growth, introducing the business foundation that will be the main driver of strategy implementation and the organizational structure and financial strategy that will support the steady implementation of the strategies, and explaining how Santen intends to create additional value for patients and society. Santen will continue to dedicate itself to effective communication with stakeholders and the creation of corporate value in pursuit of "Happiness with Vision".

Overview of Santen Report 2023:


  • Learn more about how Santen continues to tackle social issues relating to eye health, and how we leverage our strengths to contribute to patients based on our CORE PRINCIPLE and WORLD VISION.

Target & Strategy

  • Message from Takeshi Ito, President and CEO, and explanation of the new Medium-Term Management Plan (MTP) (FY2023 - FY2025), the compass for renewed growth.
  • Message from Kazuo Koshiji, Chief Financial Officer, explaining the financial strategies that will support the implementation of the new MTP.
  • Overview of the updated value creation process based on Santen’s new management structure and strategy, with specific examples that serve as the basis for our strategic framework: 1) Establishing Commercial Excellence in All Regions, 2) Product Development Aimed at Providing Value to Patients, and 3) Product Manufacturing Ensuring High Quality and Stable Supply.

Social & Environment

  • Overview of Santen’s sustainability strategy, which endeavors to contribute to the sustainable development of society and increase corporate value over the medium to long term. In terms of ESG materialities, the most important are “market penetration of products with social significance,” which will lead to realization of the new MTP and sustainable growth beyond it, and “human resource development and promotion,” which will support and drive our business growth.
  • Overview of how Santen utilizes human capital, a critical element for reinforcing our organizational strength and driving sustainable growth, with a focus on initiatives related to the development and promotion of human resources, including our unique employee training program, “Blind Experience,” which was implemented globally in FY2022.
  • Overview of health management activities, such as eye examinations for all employees in Japan, as well as initiatives for environmental conservation at production sites toward the realization of a sustainable society.

Corporate Governance

  • Message from the Chairman of the Board of Directors and inaugural messages from new Corporate Auditors and Chief Operating Officer (COO) Rie Nakajima, and a dialogue with Outside Directors on discussions at Board of Directors meetings, the Board’s effectiveness, and how it intends to support Santen’s future growth.

About Santen
As a specialized company dedicated to eye health, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries and regions. Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, Santen aims to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.
For more information, please visit Santen’s website (

Corporate Communications
Santen Pharmaceutical Co., Ltd.